Alimera Sciences submits MAA for Iluvien to MHRA Alimera Sciences.

Applications have also been submitted to the following other Concerned Member States in the European Union: Austria, France, Germany, Italy, Spain and Portugal. Related StoriesGenetic carrier screening: an interview with Don Hardison, CEO of Great Start GeneticsDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixUsing integrated molecular pathology to manage incidental pancreatic cysts: an interview with Dr Ananya Das’This MAA submission closely comes after the submission of our NDA to the U.S. Food and Drug Administration the other day, and marks an important first rung on the ladder toward the availability of a sustained launch treatment for DME individuals in Europe,’ said Dan Myers, cEO and president of Alimera.ACP may be the largest medical-specialty organization and second-largest doctor group in the United States. The organization’s MHB 2.0 is an online tool designed to help small and large PCMH methods improve patient care. ‘ACP is very pleased to end up being collaborating with CareFirst to get the PCMH program,’ said Michael S. Barr, Senior Vice President, Medical Practice, Professionalism and Quality Improvement for the ACP. ‘We anticipate interacting with procedures through eight regional meetings and a series of webinars being organized to reinforce a few of the practice change principles advanced through the Medical House Builder.’..